Logo image
Back
Symptoms 6 Weeks After COVID-19 are Reduced Among US Healthcare Personnel Receiving Additional Vaccine Doses during the Omicron Period, December 2021–April 2022
Journal article   Open access   Peer reviewed

Symptoms 6 Weeks After COVID-19 are Reduced Among US Healthcare Personnel Receiving Additional Vaccine Doses during the Omicron Period, December 2021–April 2022

Nicholas M Mohr, Ian D Plumb, Eliezer Santos Leon, Malea Pinckney, Karisa K Harland, Anusha Krishnadasan, Karin F Hoth, Kelli Wallace, Fernand Rwamwejo, J Priyanka Vakkalanka, …
Open forum infectious diseases, Vol.11(10), ofae545
09/27/2024
DOI: 10.1093/ofid/ofae545
PMCID: PMC11481461
PMID: 39416989
url
https://doi.org/10.1093/ofid/ofae545View
Published (Version of record) Open Access

Abstract

Abstract Background The objective of this study was to test the hypothesis that subsequent doses of the COVID-19 vaccine are associated with lower incidence of COVID-19-like symptoms at 6 weeks after infection. Methods This study was a case-control analysis of health care personnel in an ongoing multicenter COVID-19 vaccine effectiveness study. We enrolled participants at the time of COVID-19–like symptoms between December 19, 2021, and April 27, 2022, which corresponded to the early Omicron-predominant period after original monovalent SARS-CoV-2 additional vaccination doses became available. Our outcome was self-reported symptoms completed 6 weeks after the onset of symptoms. Results We enrolled 2,478 participants, of which 1,422 (57%) had COVID-19. The prevalence of symptoms at 6 weeks was 26% (n=373) in those with COVID-19 and 18% (n=195) in those without COVID-19. Fatigue (11%) and difficulty sleeping (7%) were most strongly associated with COVID-19. A total of 1,643 (66%) of participants had received a subsequent vaccine dose (after the primary series). Participants with COVID-19 who had received a subsequent vaccination had lower odds of symptoms at 6 weeks (adjusted odds ratio [aOR] 0.55, 95% confidence interval [95% CI] 0.43–0.70), but this relationship was not observed in those without COVID-19 (aOR 0.87, 95% CI 0.59–1.29). Conclusions Health care personnel who received subsequent doses of original monovalent COVID-19 vaccine had a lower prevalence of symptoms at 6 weeks than those that did not.
 COVID-19 post-acute COVID-19 syndrome COVID-19 vaccines vaccine efficacy

Details

Metrics

59 Record Views
Logo image